MARINELA contact CAPANU
Affiliation: Memorial Sloan-Kettering Cancer Center
- Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) StudySharon N Teraoka
Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908 0717, USA
Breast Cancer Res 13:R114. 2011..A subset of these SNPs, selected upon their main effects on contralateral breast cancer risk was further evaluated for interaction with treatment modalities and estrogen receptor (ER) status...
- Misspecification tests for binomial and beta-binomial modelsMarinela Capanu
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Stat Med 27:2536-54. 2008..Our findings suggest that IOS is strongly competitive, not only against the IM test but also against tests designed for specific binomial and beta-binomial models...
- The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanomaMarinela Capanu
Memorial Sloan Kettering Cancer Center, 307 E 63rd Street, New York, NY 10021, U S A
Stat Med 27:1973-92. 2008..However, further research is needed to validate the application of asymptotic methods to such sparse data...
- Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood methodMarinela Capanu
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biometrics 67:371-80. 2011....
- Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinomaNancy E Kemeny
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 27:3465-71. 2009..Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability...
- Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialGhassan K Abou-Alfa
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
JAMA 304:2154-60. 2010..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
- Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinomaManish A Shah
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
J Clin Oncol 29:868-74. 2011..To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with advanced gastroesophageal malignancies...
- Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancerNancy E Kemeny
Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
J Clin Oncol 29:884-9. 2011..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)...
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagusDavid H Ilson
Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 117:1409-14. 2011..Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer...
- Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 24:5201-6. 2006..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma...
- Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastasesDavid J Gallagher
Department of Medicine, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA
Ann Surg Oncol 16:1844-51. 2009..We investigated the relation between response to neoadjuvant chemotherapy and overall survival (OS) in patients with colorectal liver metastases (CLM)...
- Variation of breast cancer risk among BRCA1/2 carriersColin B Begg
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
JAMA 299:194-201. 2008..The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers...
- Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancerGeoffrey Y Ku
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Chemother Pharmacol 62:875-80. 2008..We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer...
- Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology studyJonine L Bernstein
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St Fl 3, New York, NY 10065, USA
J Natl Cancer Inst 102:475-83. 2010..We investigated whether genetic variants in ATM play a clinically significant role in radiation-induced contralateral breast cancer in women...
- Advanced hepatocellular carcinoma: which staging systems best predict prognosis?Fidel David Huitzil-Melendez
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 28:2889-95. 2010..Many staging systems that include both aspects have been developed. It remains unknown, however, which of these systems is optimal for predicting patient survival...
- Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancerDerek G Power
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Weil Cornell Medical College of Cornell University, New York, NY, USA
J Am Coll Surg 208:173-8. 2009..Laparoscopy is a recommended staging evaluation to identify occult peritoneal metastatic disease. We determined if endoscopic ultrasound (EUS) could improve the selection of patients for laparoscopy...
- Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology StudyLisbeth Bertelsen
Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
J Natl Cancer Inst 100:32-40. 2008..However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status...
- Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study GroupJane C Figueiredo
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
J Clin Oncol 26:1411-8. 2008..To investigate whether oral contraceptive (OC) use and postmenopausal hormones (PMH) are associated with an increased risk of developing asynchronous bilateral breast cancer among women diagnosed with breast cancer younger than 55 years...
- Variants in the ATM gene associated with a reduced risk of contralateral breast cancerPatrick Concannon
Department of Biochemistry and Molecular Genetics and Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia 22908 0733, USA
Cancer Res 68:6486-91. 2008..1-0.6; c.6348-54T>C RR, 0.2; 95% CI, 0.1-0.8]. These data suggest that some alleles of ATM may exert an antineoplastic effect, perhaps by altering the activity of ATM as an initiator of DNA damage responses or a regulator of p53...
- Reproductive history and risk of second primary breast cancer: the WECARE studyJoan A Largent
Epidemiology Division, Department of Medicine, University of California, Irvine, Irvine, CA 92697 7555, USA
Cancer Epidemiol Biomarkers Prev 16:906-11. 2007..Women with an initial breast cancer diagnosis are at elevated risk of developing subsequent cancer in the contralateral breast. Studies of reproductive factors and contralateral breast cancer (CBC) have provided inconsistent results...
- Estimating Cancer Risks of Rare Genetic VariantsMARINELA contact CAPANU; Fiscal Year: 2010..The research will involve hierarchical statistical modeling, a technique that aggregates the evidence about lots of rare mutations to increase the ability to predict the effects of each mutation individually. ..